We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd)
Active ingredients
palopegteriparatide
Date of review outcome
Lapse date
Type
Priority review
Indication
A prodrug providing sustained release of parathyroid hormone (PTH(1-34)), is a PTH replacement therapy indicated for the treatment of hypoparathyroidism in adults
Therapeutic area
Endocrinology